December 05, 2016 10:48 AM ET

Pharmaceuticals

Company Overview of Zoetis Inc.

Company Overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia,...

100 Campus Drive

Florham Park, NJ 07932

United States

Founded in 1952

9,000 Employees

Phone:

973-822-7000

Key Executives for Zoetis Inc.

Chief Executive Officer and Director
Age: 65
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice President
Total Annual Compensation: $436.1K
President of International Operations and Executive Vice President
Age: 49
Total Annual Compensation: $558.9K
President of US Operations and Executive Vice President
Age: 45
Total Annual Compensation: $625.5K
President of Research & Development and Executive Vice President
Age: 55
Total Annual Compensation: $499.6K
Compensation as of Fiscal Year 2015.

Zoetis Inc. Key Developments

Zoetis Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended October 2, 2016; Updates Earnings Guidance for 2016 and 2017

Zoetis Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended October 2, 2016. The company reported revenue of $1.2 billion for the third quarter of 2016, an increase of 2% compared with the third quarter of 2015 of $1.214 billion. Net income for the third quarter of 2016 was $239 million, or $0.48 per diluted share compared to $189 million or $0.48 per diluted share. Income before provision for taxes on income was $333 million against $273 million a year ago. Adjusted net income attributable to was $258 million or $0.52 per diluted share against $252 million or $0.50 per diluted share a year ago. For the nine months, the company reported revenue of $3,611 million against $3,491 million a year ago. Income before provision for taxes on income was $22 million against $997 million a year ago. Net income attributable to was $26 million or $1.34 per diluted share against $667 million or $0.63 per diluted share a year ago. Adjusted net income attributable to was $743 million or $1.49 per diluted share against $675 million or $1.34 per diluted share a year ago. Based on the strong performance through the first nine months, the company is raising its earnings guidance for 2016 and improving its earnings guidance for 2017 despite the impact of foreign currency. The company's guidance for the full year 2016 has been updated to reflect the company’s strong performance throughout the year, the continued strength of its business model, and its confidence in the outlook for the remainder of the year. The company’s guidance for the full year 2016 is: Revenue of between $4.850 billion to $4.900 billion; reported diluted EPS for the full year of between $1.66 to $1.75 per share; adjusted diluted EPS for the full year between $1.91 to $1.96 per share, net income of $830 million to $875 million, adjusted net income of $955 million to $980 million, effective tax rate of 34% and adjusted effective tax rate of 32%. The company is improving its adjusted earnings guidance for 2017 despite the negative impact of foreign currency. The company’s guidance for the full year 2017 is as follows: Revenue of between $5.150 billion to $5.275 billion; reported diluted EPS for the full year of between $2.10 to $2.22 per share; adjusted diluted EPS for the full year between $2.28 to $2.38 per share. The company expects effective tax rate on adjusted income of approximately 30%, adjusted net income of $1,135 million to $1,190 million and net income of $1,045 million to $1,110 million. The company expects to achieve operational revenue growth, including the impact from products rationalization of 4% to 5% and adjusted EBIT margin of approximately 32% and operational growth in adjusted net income of 12% to 15%.

Zoetis Inc Declares Fourth Quarter 2016 Dividend, Payable on December 1, 2016

The Board of Directors of Zoetis Inc. has declared a fourth quarter 2016 dividend payable to holders of the company’s common stock of $0.095 per share. The dividend is to be paid on December 1, 2016, to holders of record on November 3, 2016.

Zoetis Inc. to Report Q3, 2016 Results on Nov 02, 2016

Zoetis Inc. announced that they will report Q3, 2016 results at 8:30 AM, Eastern Daylight on Nov 02, 2016

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 8, 2016
Scandinavian Micro Biodevices ApS
Merger/Acquisition
January 14, 2016
Manufacturing Site in Hsinchu, Taiwan
Merger/Acquisition
January 5, 2016
Zoetis Inc., Select Brands and Manufacturing Operations In Haridwar
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Zoetis Inc., please visit www.zoetis.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.